UPTRAVI 200 µG, Comprimé pélliculé


--- Description
Pack Boite de 140
Strength (Dosage) 200 µG
Laboratory MAPHAR
Ingredients Sélexipag
Therapeutic class Antihypertenseur pulmonaire, agoniste sélectif du récepteur IP
ATC code B01AC27
PPH $6,580.10
PPV $6,710.90
Refundable No
Refund base $0.00
Refund rate $0.00
Table A
Marketing status Commercialized
Type Not specified
Uses Traitement de l'hypertension artérielle pulmonaire (HTAP) chez les patients atteints d'une limitation fonctionnelle avancée (classe fonctionnelle III/IV de la NYHA) pour retarder la progression de la maladie.
Side effects

Medications with one or more of the ingredients above

Medications under one or more of the therapeutic classes above

Medications from the same laboratory

The materials provided by this website,, are for informational purposes only and are not provided as legal advice or medical advice. No reader should act on the basis of this material without seeking appropriate professional advice with respect to the particular facts and applicable law. The materials are not presented as correct, complete or up-to-date, and are not a substitute for a visit or consultation with a physician or health professional.